It is a pharma private limited company based in Panchkula, Haryana, India, established in 2020.
2020 | Panchkula, Haryana, India | ActiveAstrazen Pharmaceuticals Private Limited, a active private limited company, was established on 13 October 2020 in Panchkula, Haryana, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24290HR2020PTC090053. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹2.50 M and a paid-up capital of ₹1.00 M.
It upholds a compliant status. Its leadership includes Shailja Tiwari (Director), Paras Nath Tiwary (Director), Nirmal Kumar Nirala (Director). Past directors included Shailja Tiwari, Paras Nath Tiwary, Nirmal Kumar Nirala. It holds ₹1.25 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at House 547, Sector 12A, Panchkula, Haryana, 134113.
U24290HR2020PTC090053
090053
13 October 2020
₹2.50 M
₹1.00 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Astrazen Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shailja Tiwari | Director | 14 Mar 2023 | Current |
| Paras Nath Tiwary | Director | 16 Dec 2022 | Current |
| Nirmal Kumar Nirala | Director | 27 Dec 2023 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 29 Sep 2023 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2023 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2024 | Past |
| Pramod Abcsdd | Director | 14 Mar 2023 | Past |
| Pramod Abcsdd | Director | 16 Dec 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Astrazen Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 905.5% increase. The company also saw a substantial improvement in profitability, with a 191.75% increase in profit. The company's net worth moved up by a moderate rise of 9.06%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
Unlock access to Astrazen Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Reveal ownership structures and financial performance - Get instant access now!
₹12,500,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Apr 2021 | Canara Bank | ₹1.25 Cr | Open |
Explore comprehensive loan charge details -
Astrazen Pharmaceuticals has a workforce of 0 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Astrazen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Astrazen Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Astrazen Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Progress on Astrazen Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was documented.
The activity Nirmal Kumar Nirala was appointed as a Director was appointed as a Director on 27 Dec 2023 & has been associated with this company since 1 year 11 months . was completed.
The activity A charge with Canara Bank of Rs. 12.50 M registered on 21 Apr 2021 with Charge ID 100457498 was modified on 05 May 2023. was completed.
Shailja Tiwari was appointed as a Director was appointed as a Director on 14 Mar 2023 & has been associated with this company since 2 years 9 months . was recorded as a recent event.
Progress on Paras Nath Tiwary was appointed as a Director was appointed as a Director on 16 Dec 2022 & has been associated with this company since 3 years 6 days . was documented.
The CIN of Astrazen Pharmaceuticals Private Limited is U24290HR2020PTC090053.
Astrazen Pharmaceuticals Private Limited is headquartered at House 547, Sector 12A, Panchkula, Haryana, 134113.
Astrazen Pharmaceuticals Private Limited was incorporated on 13 October 2020.
The current directors of Astrazen Pharmaceuticals Private Limited are
The primary industry of Astrazen Pharmaceuticals Private Limited is Manufacturing.
Astrazen Pharmaceuticals Private Limited is unlisted.
The authorized capital of Astrazen Pharmaceuticals Private Limited is ₹2.50 M, and the paid-up capital is ₹1.00 M.
The compliance status of Astrazen Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX